Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 5, 2026, where all three proposals were approved. Stockholders elected three Class III directors, ratified Ernst & Young LLP as the independent auditor for fiscal year 2026, and approved the compensation of named executive officers on a non-binding advisory basis. Additionally, the Board approved revisions to the Non-Employee Director Compensation Program to attract and retain qualified directors, effective as of the Annual Meeting.

Arcutis Biotherapeutics, Inc. reported granting an aggregate of 44,000 restricted stock units (RSUs) to six newly hired employees. These awards were approved by the Compensation Committee of the Board of Directors and granted under the 2022 Inducement Plan. The RSUs serve as a material inducement for the new employees and will vest over four years, with 25% vesting on each annual anniversary, contingent on continuous employment.

Arcutis Biotherapeutics announced that its management will present at the Goldman Sachs 47th Annual Global Healthcare Conference. The fireside chat is scheduled for Tuesday, June 9, 2026, at 2:00 p.m. ET. A webcast of the presentation will be available on the company's website, with a replay accessible for 180 days following the conference.

Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 269,000 restricted stock units and options to purchase 70,000 shares of common stock to 40 newly hired employees. These awards were approved by the Compensation Committee and granted under the 2022 Inducement Plan on May 1, 2026. The restricted stock units vest over four years, while the stock options vest over four years with a one-year cliff and monthly installments thereafter, both subject to continuous employment.

Arcutis Biotherapeutics reported strong first-quarter 2026 financial results, with product revenue increasing significantly and net loss narrowing. The company achieved positive net cash flow from operating activities for the quarter, a substantial improvement from the prior year. This performance was supported by the commercialization of ZORYVE across various formulations and indications, including recent launches for atopic dermatitis and scalp & body psoriasis. Arcutis also initiated a Phase 1a/1b clinical trial for ARQ-234 in atopic dermatitis, triggering a $10.0 million milestone payment.

Arcutis Biotherapeutics reported Q1 2026 ZORYVE net product revenue of $105.4 million, marking a 65% year-over-year increase despite a 17% sequential decline attributed to typical Q1 seasonality. The company submitted a supplemental New Drug Application (sNDA) for ZORYVE cream 0.05% to expand its indication for atopic dermatitis in infants aged 3 to 24 months and initiated a Phase 1a/1b study for ARQ-234. Arcutis also completed its dermatology sales force expansion, began building a primary care and pediatrics-focused team, and maintained positive operating cash flow of $2.2 million for the quarter.

Arcutis Biotherapeutics announced that its ZORYVE® (roflumilast) cream received a strong recommendation in the American Academy of Dermatology (AAD) clinical practice guidelines for pediatric atopic dermatitis. The guidelines recommend ZORYVE cream for children aged 2-5 years and 6 years and older, citing its proven efficacy, safety, and tolerability as a steroid-free topical PDE4 inhibitor. This endorsement reinforces ZORYVE's value for long-term use in managing this chronic condition affecting approximately 9.6 million U.S. children.